SARCLISA Takes Center StageThe treatment landscape for multiple myeloma has seen groundbreaking shifts, with SARCLISA (isatuximab-irfc) emerging as a key player. SARCLISA, a monoclonal antibody targeting CD38, has delivered promising results when used in combination therapies for relapsed or refractory multiple myeloma. Its approval marks one of the most significant advances in the...